Back

Sex-differences from referral to tafamidis treatment outcomes in real-world patients with wild-type transthyretin amyloid cardiomyopathy.

12 May 2024 (09:45 - 09:54)
Organised by: Logo
Congress Presentation Part of: Evaluation of prognosis in cardiomyopathies Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Philippe Debonnaire

AZ Sint Jan, Brugge (Belgium)

4 More presentations in this session

Presentation thumbnail
Prevalence and prognostic implications of right ventricular systolic dysfunction and reverse remodeling in dilated cardiomyopathy: a longitudinal prospective cardiac magnetic resonance investigation
Doctor E. Dziewiecka (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy
Doctor M. Setti (Verona, IT)
Abstract Slides Video
Presentation thumbnail
Exercise intensity and cardiac disease development in carriers of titin variants
Doctor G. Savonitto (Stockholm, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance and genetics: an integrated approach to predict left ventricular reverse remodeling in dilated cardiomyopathy
Doctor M. Iseppi (Trento, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Evaluation of prognosis in cardiomyopathies
Video

The Event

Event poster

Heart Failure 2024

12 May 2024 09:45 CET
You may be interested in
thumbnail
Congress Presentation
Consistent efficacy of vutrisiran across sexes in transthyretin cardiac amyloidosis: evidence from the HELIOS-B trial
thumbnail
Congress Presentation
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study
thumbnail
Congress Presentation
Gender differences in transthyretin cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources